Platinum resistance needs the mythbusters [Letter to the Editor]

Article

Stordal, B. and Davey, R. 2008. Platinum resistance needs the mythbusters [Letter to the Editor]. Toxicology letters. 180 (3), p. 230. https://doi.org/10.1016/j.toxlet.2008.07.003
TypeArticle
TitlePlatinum resistance needs the mythbusters [Letter to the Editor]
AuthorsStordal, B. and Davey, R.
Abstract

Letter to the Editor

Keywordscisplatin; oxaliplatin; resistance
Research GroupBiomarkers for Cancer group
PublisherElsevier
JournalToxicology letters
ISSN0378-4274
Publication dates
Online10 Jul 2008
Print28 Aug 2008
Publication process dates
Deposited08 Jan 2016
Accepted27 Jun 2008
Output statusPublished
Accepted author manuscript
License
Copyright Statement

© 2008. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/

Digital Object Identifier (DOI)https://doi.org/10.1016/j.toxlet.2008.07.003
PubMed ID18662757
Web of Science identifierWOS:000259461000010
LanguageEnglish
Permalink -

https://repository.mdx.ac.uk/item/84z98

Log in to edit

Download files

Accepted author manuscript
2008 Stordal - Toxicology Letters.pdf
License: CC BY-NC-ND 4.0

  • 55
    total views
  • 13
    total downloads
  • 5
    views this month
  • 2
    downloads this month

Export as

Related outputs

Breast cancer risk and prevention in 2024: An overview from the Breast Cancer UK ‐ Breast Cancer Prevention Conference
Stordal, B., Harvie, M., Antoniou, M.N., Bellingham, M., Chan, D.S.M., Darbre, P., Karlsson, O., Kortenkamp, A., Magee, P., Mandriota, S., Silva, E., Turner, J.E., Vandenberg, L.N. and Evans, D.G. 2024. Breast cancer risk and prevention in 2024: An overview from the Breast Cancer UK ‐ Breast Cancer Prevention Conference. Cancer Medicine. 13 (18). https://doi.org/10.1002/cam4.70255
The efficacy of gemcitabine and docetaxel chemotherapy for the treatment of relapsed and refractory osteosarcoma: a systematic review and pre‐clinical study
Low, K., Foulkes, P., Hills, F., Roberts, H. and Stordal, B. 2024. The efficacy of gemcitabine and docetaxel chemotherapy for the treatment of relapsed and refractory osteosarcoma: a systematic review and pre‐clinical study. Cancer Medicine. 13 (18). https://doi.org/10.1002/cam4.70248
Chromosomal copy number and mutational status are required to authenticate ovarian cancer cell lines as appropriate cell models
Stordal, B., Farrelly, A. and Hennessy, B. 2024. Chromosomal copy number and mutational status are required to authenticate ovarian cancer cell lines as appropriate cell models. Molecular Biology Reports. 51 (1). https://doi.org/10.1007/s11033-024-09747-4
Ovarian cancer: identifying and managing familial and genetic risk
Slade, E., Berg, L., Dworzynski, K., Manchanda, R., Barber, V., Bowen, R., Brentnall, A., Cameron, A., Davies, D., Davies, M., Evans, D., Hayward, J., McCluggage, W., Miles, T., Monahan, K., Moses, D., Robb, F., Rosenthal, A., Side, L., Stanford, J., Stordal, B. and Tripathi, V. 2024. Ovarian cancer: identifying and managing familial and genetic risk. National Institute for Health and Care Excellence.
Ovarian cancer: identifying and managing familial and genetic risk—summary of new NICE guidance
Slade, E., Berg, L., Dworzynski, K., Manchanda, R., Barber, V., Bowen, R., Brentnall, A., Cameron, A., Davies, D., Davies, M., Evans, D., Hayward, J., McCluggage, W., Miles, T., Monahan, K., Moses, D., Robb, F., Rosenthal, A., Side, L., Stanford, J., Stordal, B. and Tripathi, V. 2024. Ovarian cancer: identifying and managing familial and genetic risk—summary of new NICE guidance. British Medical Journal. 385. https://doi.org/10.1136/bmj.q807
Awareness of ovarian cancer symptoms and risk factors in a young ethnically diverse British population
Radu, C., Matos de Melo Fernandes, N., Khalfe, S. and Stordal, B. 2023. Awareness of ovarian cancer symptoms and risk factors in a young ethnically diverse British population. Cancer Medicine. 12 (8), pp. 9879-9892. https://doi.org/10.1002/cam4.5670
Establishment and characterization of single and triple‐agent resistant osteosarcoma cell lines
Low, K., Hills, F., Roberts, H. and Stordal, B. 2023. Establishment and characterization of single and triple‐agent resistant osteosarcoma cell lines. Advanced Biology. 7 (2). https://doi.org/10.1002/adbi.202200194
Breastfeeding reduces the risk of breast cancer: a call for action in high-income countries with low rates of breastfeeding
Stordal, B. 2023. Breastfeeding reduces the risk of breast cancer: a call for action in high-income countries with low rates of breastfeeding. Cancer Medicine. 12 (4), pp. 4616-4625. https://doi.org/10.1002/cam4.5288
Biomedical Science Exchanges at Middlesex University London
Stordal, B. 2019. Biomedical Science Exchanges at Middlesex University London. REALISE: Seminar on International Staff Mobility. Universities UK Boardroom, Woburn House, WC1H 9HQ, London
Biomedical Science Exchanges
Stordal, B. 2018. Biomedical Science Exchanges. Middlesex University’s Erasmus Staff Training Week 2018. Middlesex University London
Biomedical Science Exchanges
Stordal, B. 2018. Biomedical Science Exchanges. Middlesex University Staff Conference 2018: Learning through Change. Middlesex University London 27 Mar 2018
Comparison of formative multiple choice questions using online platforms vs summative assessment: experience from an anatomy and physiology module
Stordal, B. 2015. Comparison of formative multiple choice questions using online platforms vs summative assessment: experience from an anatomy and physiology module. Middlesex University Annual Learning and Teaching Conference 2015: Revisiting Assessment. London, UK 13 Jul 2015
Overcoming chemoresistance in osteosarcoma: the role of autophagy in cell death or survival following chemotherapy
Rosa, G., Burczynska, B., Stordal, B. and Roberts, H. 2018. Overcoming chemoresistance in osteosarcoma: the role of autophagy in cell death or survival following chemotherapy. Research Degrees Students' Summer Conference. Middlesex University, London, UK 04 Sep 2018
ROR1-A novel biomarker for chemoresistance in ovarian cancer
Shafat, E., Hills, F. and Stordal, B. 2018. ROR1-A novel biomarker for chemoresistance in ovarian cancer. Research Degrees Students' Summer Conference. Middlesex University, London, UK 04 Sep 2018
Optimisation of a selection strategy for drug resistance osteosarcoma cell lines
Low, K., Hills, F., Roberts, H. and Stordal, B. 2018. Optimisation of a selection strategy for drug resistance osteosarcoma cell lines. Research Degrees Students' Summer Conference. Middlesex University, London, UK 04 Sep 2018
Mechanisms of apoptosis and autophagy in chemoresistant ovarian cancer cells
Bennacer, A., Roberts, H. and Stordal, B. 2018. Mechanisms of apoptosis and autophagy in chemoresistant ovarian cancer cells. Research Degrees Students' Summer Conference. Middlesex University, London, UK 04 Sep 2018
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: Diagnostics guidance [DG34]
Nixon, F., Albrow, R., Donna, B., Kroese, D., Adair, E., Bagshaw, J., Carrol, E., Driskell, O., Edwards, S., Fleming, S., Gray, J., Halligan, S., Hitchman, J., Hyde, C., McGinley, P., Messenger, M., Moseley, A., Naylor, P., Neely, D., Rahman Haley, S., Richards, S., Sculpher, M., Stevenson, M., Summerton, N., Wierzbicki, A., Bramley, M., Graham, J., Pepper, L., Ryyan, D., Stordal, B., Van Mann, U. and Wardley, A. 2018. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: Diagnostics guidance [DG34]. NICE.
Cross resistance between cisplatin and oxaliplatin in a low-level resistance lung cancer cell model
Stordal, B., Davey, M. and Davey, R. 2005. Cross resistance between cisplatin and oxaliplatin in a low-level resistance lung cancer cell model. 96th AACR Annual Meeting. Anaheim California 16 - 20 Apr 2005 American Association for Cancer Research (AACR). pp. 348-349
Oxaliplatin and cisplatin cause similar chromosomal changes in H69 SCLC cells: linking changes in genotype to the resistant phenotype
Stordal, B., Peters, G., St. Heaps, L. and Davey, R. 2006. Oxaliplatin and cisplatin cause similar chromosomal changes in H69 SCLC cells: linking changes in genotype to the resistant phenotype. 97th AACR Annual Meeting. Washington D.C., USA 01 - 05 Apr 2006 American Association for Cancer Research (AACR). pp. 133
BRCA1/2 mutation analysis in 43 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation
Stordal, B., Timms, K., Renuad, M., Thery, J., Farrelly, A., Williams, D., Potter, J., Tran, T., Korpanty, G., Cremona, M., Carey, M., Li, J., Li, Y., Aslan, O., O'Leary, J., Mills, G. and Hennessy, B. 2012. BRCA1/2 mutation analysis in 43 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. 103rd Annual Meeting of the American Association for Cancer Research (AACR). Chicago 31 Mar - 04 Apr 2012 American Association for Cancer Research (AACR). https://doi.org/10.1158/1538-7445.AM2012-78
A systematic approach to the study of cancer stem cells applied to ovarian cancer
Ffrench, B., Cooke, A., Stordal, B., O'Toole, S., Sheils, O., Gallagher, M. and O'Leary, J. 2012. A systematic approach to the study of cancer stem cells applied to ovarian cancer. 103rd Annual Meeting of the American Association for Cancer Research (ACCR). Chicago, USA 31 Mar - 04 Apr 2012 American Association for Cancer Research (AACR). https://doi.org/10.1158/1538-7445.AM2012-3382
Overcoming chemoresistance in osteosarcoma: the role of autophagy in cell death or survival following chemotherapy
Rosa, G., Burczynska, B., Stordal, B. and Roberts, H. 2018. Overcoming chemoresistance in osteosarcoma: the role of autophagy in cell death or survival following chemotherapy. 2018 NCRI Cancer Conference. Glasgow, Scotland 04 - 06 Nov 2018
ROR1- A biomarker for chemoresistance in ovarian cancer
Syed, E., Hills, F. and Stordal, B. 2018. ROR1- A biomarker for chemoresistance in ovarian cancer. 2018 NCRI Cancer Conference. Glasgow, Scotland 04 - 06 Nov 2018
Optimisation of a selection strategy for drug resistance osteosarcoma cell lines
Low, K., Hills, F., Roberts, H. and Stordal, B. 2019. Optimisation of a selection strategy for drug resistance osteosarcoma cell lines. 2019 NCRI Cancer Conference. Glasgow, UK 03 - 05 Nov 2019
The EMT­activator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but predictive of survival
Rae, S., Keenan, J., Spillane, C., Blackshields, G., Madden, S. and Stordal, B. 2015. The EMT­activator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but predictive of survival. 2015 NCRI Cancer Conference. Liverpool, UK 01 - 03 Nov 2015
BRCA1 promoter methylation and clinical outcomes in epithelial ovarian cancer a pooled analysis of individual patient data
Kalachand, R., Stordal, B., Madden, S., Chandler, B., Cunningham, J., Goode, E., Ruscito, I., Braicu, E., Sehouli, J., Ignatov, A., Yu, H., Katsaros, D., Lu, L., Mills, G., Broaddus, R., Lu, K., Carey, M., Timms, K., Rzepecka, I., Kupryjanczyk, J., Swisher, E., Harrell, M., Agnew, K., O'Riain, C., O'Toole, S., O'Leary, J., Thomas, D., Chaudhry, P., Srinivasan, R. and Hennessy, B. 2019. BRCA1 promoter methylation and clinical outcomes in epithelial ovarian cancer a pooled analysis of individual patient data. Lorne Cancer Conference. Lorne, Victoria, Australia 14 - 16 Feb 2019
Comparative selection strategies for development of platinum-drug resistant ovarian cancer cell lines
Busschots, S., Kalachand, R., O'Toole, S., O'Leary, J., Hennessy, B. and Stordal, B. 2017. Comparative selection strategies for development of platinum-drug resistant ovarian cancer cell lines. 12th International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy. Sydney, Australia 10 - 14 Dec 2017
PO-495 PI3K pathway upregulation mediates acquired resistance to platinum agents and polyadenoribose polymerase inhibitors (PARPi) in BRCA1-methylated ovarian cancer (OC)
Kalachand, R., Cremona, M., Farrelly, A., Eustace, A., Stordal, B. and Hennessy, B. 2018. PO-495 PI3K pathway upregulation mediates acquired resistance to platinum agents and polyadenoribose polymerase inhibitors (PARPi) in BRCA1-methylated ovarian cancer (OC). EACR25: The 25th Biennial Congress of the European Association for Cancer Research. Amsterdam, Netherlands 30 Jun - 03 Jul 2018
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer [Review - Intervention]
Patel, A., Kalachand, R., Busschots, S., Doherty, B., Kapros, E., Lawlor, D., Hall, N. and Stordal, B. 2022. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer [Review - Intervention]. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD008766.pub3
The EMT-activator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but is predictive of survival
Rae, S., Spillane, C., Blackshields, G., Madden, S., Keenan, J. and Stordal, B. 2022. The EMT-activator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but is predictive of survival. Human Cell. 35 (5), pp. 1547-1559. https://doi.org/10.1007/s13577-022-00744-y
Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer
Kalachand, R., O'Riain, C., Toomey, S., Carr, A., Timms, K., O'Toole, S., Madden, S., Bates, M., O'Leary, J., Gleeson, N., O'Donnell, D., Grogan, L., Breathnach, O., Farrelly, A., Stordal, B. and Hennessy, B. 2020. Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer. Obstetrics & Gynecology Science. 63 (5), pp. 643-654. https://doi.org/10.5468/ogs.20033
BRCA1 promoter methylation and clinical outcomes in ovarian cancer: an individual patient data meta-analysis
Kalachand, R., Stordal, B., Madden, S., Chandler, B., Cunningham, J., Goode, E., Ruscito, I., Braicu, E., Sehouli, J., Ignatov, A., Yu, H., Katsaros, D., Mills, G., Lu, K., Carey, M., Timms, K., Kupryjanczyk, J., Rzepecka, I., Podgorska, A., McAlpine, J., Swisher, E., Bernards, S., O'Riain, C., O'Toole, S., O'Leary, J., Bowtell, D., Thomas, D., Prieske, K., Joosse, S., Woelber, L., Chaudhry, P., Häfner, N., Runnebaum, I. and Hennessy, B. 2020. BRCA1 promoter methylation and clinical outcomes in ovarian cancer: an individual patient data meta-analysis. Journal of the National Cancer Institute. 112 (12), pp. 1190-1203. https://doi.org/10.1093/jnci/djaa070
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer [Protocol - Intervention]
Stordal, B., Kalachand, R. and Hall, N. 2018. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer [Protocol - Intervention]. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd008766.pub2
CD10−/ALDH− cells are the sole cisplatin-resistant component of a novel ovarian cancer stem cell hierarchy
Ffrench, B., Gasch, C., Hokamp, K., Spillane, C., Blackshields, G., Mahgoub, T., Bates, M., Kehoe, L., Mooney, A., Doyle, R., Doyle, B., O'Donnell, D., Gleeson, N., Hennessy, B., Stordal, B., O'Riain, C., Lambkin, H., O'Toole, S., O'Leary, J. and Gallagher, M. 2017. CD10−/ALDH− cells are the sole cisplatin-resistant component of a novel ovarian cancer stem cell hierarchy. Cell Death & Disease. 8 (10). https://doi.org/10.1038/cddis.2017.379
Non-invasive and non-destructive measurements of confluence in cultured adherent cell lines
Busschots, S., O'Toole, S., O'Leary, J. and Stordal, B. 2015. Non-invasive and non-destructive measurements of confluence in cultured adherent cell lines. MethodsX. 2, pp. 8-13. https://doi.org/10.1016/j.mex.2014.11.002
Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer
McEvoy, L., O'Toole, S., Spillane, C., Martin, C., Gallagher, M., Stordal, B., Blackshields, G., Sheils, O. and O'Leary, J. 2015. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer. BMC cancer. 15 (1). https://doi.org/10.1186/s12885-015-1539-8
Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells
Busschots, S., O'Toole, S., O'Leary, J. and Stordal, B. 2015. Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells. Experimental Cell Research. 336 (1), pp. 1-14. https://doi.org/10.1016/j.yexcr.2014.12.001
The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer
D’Adhemar, C., Spillane, C., Gallagher, M., Bates, M., Costello, K., Barry-O'Crowley, J., Haley, K., Kernan, N., Murphy, C., Smyth, P., O'Byrne, K., Pennington, S., Cooke, A., Ffrench, B., Martin, C., O'Donnell, D., Hennessy, B., Stordal, B., Finn, S., McCann, A., Gleeson, N., D'Arcy, T., Flood, B., O'Neill, L., Sheils, O., O'Toole, S. and O'Leary, J. 2014. The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer. PLoS ONE. 9 (6), pp. 1-15. https://doi.org/10.1371/journal.pone.0100816
OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets
Madden, S., Clarke, C., Stordal, B., Carey, M., Broaddus, R., Gallagher, W., Crown, J., Mills, G. and Hennessy, B. 2014. OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets. Molecular Cancer. 13 (1), pp. 1-11. https://doi.org/10.1186/1476-4598-13-241
PARP inhibitors as P-glyoprotein substrates
Lawlor, D., Martin, P., Busschots, S., Thery, J., O'Leary, J.J., Hennessy, B.T. and Stordal, B. 2014. PARP inhibitors as P-glyoprotein substrates. Journal of Pharmaceutical Sciences. 103 (6), pp. 1913-1920. https://doi.org/10.1002/jps.23952
Collateral sensitivity to cisplatin in KB-8-5-11 drug-resistant cancer cells
Doherty, B., Lawlor, D., Gillet, J., Gottesman, M., O'Leary, J. and Stordal, B. 2014. Collateral sensitivity to cisplatin in KB-8-5-11 drug-resistant cancer cells. Anticancer Research. 34 (1), pp. 503-507.
In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: a practical guide with case studies
McDermott, M., Eustace, A., Busschots, S., Breen, L., Crown, J., Clynes, M., O'Donovan, N. and Stordal, B. 2014. In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: a practical guide with case studies. Frontiers in Oncology. 4, pp. 1-16. https://doi.org/10.3389/fonc.2014.00040
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation
Stordal, B., Timms, K., Farrelly, A., Gallagher, D., Busschots, S., Renaud, M., Thery, J., Williams, D., Potter, J., Tran, T., Korpanty, G., Cremona, M., Carey, M., Li, J., Li, Y., Aslan, O., O'Leary, J., Mills, G. and Hennessy, B. 2013. BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. Molecular Oncology. 7 (3), pp. 567-79. https://doi.org/10.1016/j.molonc.2012.12.007
Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein
Stordal, B., Hamon, M., McEneaney, V., Roche, S., Gillet, J., O'Leary, J., Gottesman, M. and Clynes, M. 2012. Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein. PLoS ONE. 7 (7), pp. 1-13. https://doi.org/10.1371/journal.pone.0040717
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review
Murphy, M. and Stordal, B. 2011. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review. Drug Resistance Updates. 14 (3), pp. 177-190. https://doi.org/10.1016/j.drup.2011.02.004
Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells
Egan, K., Crowley, D., Smyth, P., O'Toole, S., Spillane, C., Martin, C., Gallagher, M., Canney, A., Norris, L., Conlon, N., McEvoy, L., Ffrench, B., Stordal, B., Keegan, H., Finn, S., McEneaney, V., Laios, A., Ducrée, J., Dunne, E., Smith, L., Berndt, M., Sheils, O., Kenny, D. and O'Leary, J. 2011. Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells. PLoS ONE. 6 (10). https://doi.org/10.1371/journal.pone.0026125
ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair
Stordal, B. and Davey, R. 2009. ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair. Cancer Chemotherapy and Pharmacology. 63 (4), pp. 661-672. https://doi.org/10.1007/s00280-008-0783-x
Citations, citations everywhere but did anyone read the paper? [Letter to the Editor]
Stordal, B. 2009. Citations, citations everywhere but did anyone read the paper? [Letter to the Editor]. Colloids and surfaces. B, Biointerfaces. 72 (2), pp. 312 -312. https://doi.org/10.1016/j.colsurfb.2009.04.001
A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1
Stordal, B. and Davey, R. 2009. A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1. Current Cancer Drug Targets. 9 (3), pp. 354-365. https://doi.org/10.2174/156800909788166592
A 39 kDa fragment of endogenous ASK1 suggests specific cleavage not degradation by the proteasome
Stordal, B. and Davey, R. 2008. A 39 kDa fragment of endogenous ASK1 suggests specific cleavage not degradation by the proteasome. IUBMB Life. 60 (3), pp. 180-184. https://doi.org/10.1002/iub.24
A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship
Stordal, B., Pavlakis, N. and Davey, R. 2007. A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treatment Reviews. 33 (8), pp. 688-703. https://doi.org/10.1016/j.ctrv.2007.07.013
Understanding cisplatin resistance using cellular models
Stordal, B. and Davey, M. 2007. Understanding cisplatin resistance using cellular models. IUBMB Life. 59 (11), pp. 696-699. https://doi.org/10.1080/15216540701636287
Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review
Stordal, B., Pavlakis, N. and Davey, R. 2007. Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review. Cancer Treatment Reviews. 33 (4), pp. 347-357. https://doi.org/10.1016/j.ctrv.2007.01.009
Similar chromosomal changes in cisplatin and oxaliplatin-resistant sublines of the H69 SCLC cell line are not associated with platinum resistance
Stordal, B., Peters, G. and Davey, R. 2006. Similar chromosomal changes in cisplatin and oxaliplatin-resistant sublines of the H69 SCLC cell line are not associated with platinum resistance. Genes, Chromosomes & Cancer. 45 (12), pp. 1094-105. https://doi.org/10.1002/gcc.20373
Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells
Stordal, B., Davey, M. and Davey, R. 2006. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells. Cancer Chemotherapy and Pharmacology. 58 (2), pp. 256-265. https://doi.org/10.1007/s00280-005-0148-7